|
Nov, 2009 | Pages : 100 | Price : US$ 1200.00 |
| The future of pharma industry in the Asia-Pacific region remains bright, and the industry is projected to grow at a CAGR of around 12.6% during 2010-2012. |
| |
|
Nov, 2009 | Pages : 55 | Price : US$ 1100.00 |
| The biotech market in Malaysia is expected to grow at a CAGR of around 21% during 2010-2012. |
| |
|
Nov, 2009 | Pages : 60 | Price : US$ 1000.00 |
| The healthcare spending in the country is forecasted to grow at a CAGR of more than 13% during 2007-2012. This growth will be driven by the favourable regulatory environment. |
| |
|
Nov, 2009 | Pages : 55 | Price : US$ 1000.00 |
| The US represents the world’s largest healthcare market, with an annual spending of around US$ 2.24 Trillion in 2007. The US healthcare spending is expected to grow at a CAGR of around 4%. |
| |
|
Oct, 2009 | Pages : 105 | Price : US$ 1200.00 |
| The Chinese healthcare spending is forecast to grow at CAGR of over 18% during 2010-2012. The market is characterized by major changes in rural healthcare infrastructure. |
| |
|
Sep, 2009 | Pages : 85 | Price : US$ 1200.00 |
| The clinical trial outsourced market in India is forecasted to grow at a CAGR of around 31% during 2010-2012. Presently, the market is characterized by the dominance of phase III and phase II trials, |
| |
|
Sep, 2009 | Pages : 70 | Price : US$ 1200.00 |
| The pharmaceutical market in the region is expected to grow at a CAGR of around 11% during 2010-2012. Presently, the market is characterized by major changes in regulation policies of every country. |
| |
|
Aug, 2009 | Pages : 120 | Price : US$ 1600.00 |
| The Asia-Pacific biotech market is projected to grow at a CAGR of around 14% during 2010-2012. Currently, the industry is driven by new developing markets like Malaysia and India. |
| |
|
Aug, 2009 | Pages : 70 | Price : US$ 1200.00 |
| Over the past ten years the generic drugs have saved US$ 734 Billion for the American healthcare system. The US generics market is forecasted to grow at a CAGR of around 9.2% during 2010-2012. |
| |
|
Aug, 2009 | Pages : 85 | Price : US$ 1200.00 |
| In 2008, generics accounted for more than 51% prescriptions and around 23% sales of the total pharmaceutical market. |
| |
|
|
